Economics of antihypertensive therapy.
Antihypertensive therapy has come a long way in the past 40 years. With the wide range of drugs now available, cost has become an additional consideration in selection of therapy. However, precise figures for comparison of drugs within and between classes can be difficult and time-consuming to gather. The unit-cost tables in this article are presented with the hope that they will simplify the selection process. Of course, unit cost is not the sole criterion to be considered; potency and frequency of administration also influence the overall cost of therapy.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001581:Benzothiadiazines; D003365:Costs and Cost Analysis; D004232:Diuretics; D006801:Humans; D006973:Hypertension / Q000191:economics*; D007008:Hypokalemia / Q000139:chemically induced / Q000191:economics; D011189:Potassium Chloride / Q000008:administration & dosage; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage
D000318:Adrenergic beta-Agonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D014665:Vasodilator Agents; D011189:Potassium Chloride